R., M.; P., P. H.; R., M. H. A prospective analysis of the cost-effectiveness of alfuzosin, tamsulosin and silodosin for 12 weeks in benign prostatic hyperplasia. International Journal of Basic & Clinical Pharmacology, [S. l.], v. 5, n. 6, p. 2481–2487, 2016. DOI: 10.18203/2319-2003.ijbcp20164109. Disponível em: https://www.ijbcp.com/index.php/ijbcp/article/view/37. Acesso em: 16 apr. 2026.